AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie GAAP R&D Expense % of Net Revenues by Quarter
GAAP R&D Expense % of Net Revenues (%) (%)
AbbVie GAAP R&D Expense % of Net Revenues: 13.8% in Q2 2026, unchanged from a year earlier.
Latest, Q2 2026
13.8%
Period ended Jun 30, 2026
Change on a year earlier
0.0 pts
13.8% in Q2 2025
History
11 quarters
Since Q3 2022
Sources
11
Documents cited below
Where the Q2 2026 figure comes from
“On a GAAP basis, research and development (R&D) expense was 13.8 percent of net revenues. The adjusted R&D expense was 13.6 percent of net revenues.”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Earnings Release.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie GAAP R&D Expense % of Net Revenues (%), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd-gaap-pct-rev
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.